Skip to main
PACB
PACB logo

PACB Stock Forecast & Price Target

PACB Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 20%
Buy 40%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

Pacific Biosciences of California Inc. is experiencing positive trends in the placement and utilization of its Revio sequencing platform, which is crucial for both near-term guidance and long-term targets through 2026. The company has expressed confidence in returning to growth this year, which is supported by its strong organic profile and recent strategic acquisitions that suggest potential for further market expansion. Although management may adopt a conservative approach to initial 2024 guidance due to the uncertain macro environment, the overall trajectory indicates a robust outlook for the company's financial performance.

Bears say

Pacific Biosciences faces significant risks related to stagnant utilization rates and potentially weaker demand for its instruments, which pose a threat to meeting its 2026 financial targets. Additionally, ongoing demand weaknesses, particularly in China, may persist into 2024, further damaging the company's revenue prospects if competitors introduce superior offerings. Compounding these challenges, the tightening of research budgets and reduced funding availability could limit customer purchases, negatively impacting Pacific Biosciences's growth potential.

PACB has been analyzed by 15 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 40% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pacific Biosciences of California and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pacific Biosciences of California (PACB) Forecast

Analysts have given PACB a Buy based on their latest research and market trends.

According to 15 analysts, PACB has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pacific Biosciences of California (PACB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.